Carisma Therapeutics
CARM
CARM was delisted on the 10th of October, 2025.
50 hedge funds and large institutions have $26.6M invested in Carisma Therapeutics in 2023 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 18 increasing their positions, 13 reducing their positions, and 11 closing their positions.
231% more call options, than puts
Call options by funds: $1.59M | Put options by funds: $479K
38% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 13
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.75% less ownership
Funds ownership: 23.25% → 22.5% (-0.75%)
14% less funds holding
Funds holding: 58 → 50 (-8)
33% less capital invested
Capital invested by funds: $39.6M → $26.6M (-$13M)
73% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$410K |
| 2 |
BlackRock
New York
|
+$338K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$319K |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$124K |
| 5 |
Barclays
London,
United Kingdom
|
+$94.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TOTUOP
Trustees of The University of Pennsylvania
Philaldelphia,
Pennsylvania
|
-$1.51M |
| 2 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$397K |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$279K |
| 4 |
Jane Street
New York
|
-$154K |
| 5 |
American Century Companies
Kansas City,
Missouri
|
-$66.8K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
51
Jane Street
New York
| – | -$154K | -36,328 | Closed |
|
|
52
American Century Companies
Kansas City,
Missouri
| – | -$66.8K | -15,781 | Closed |
|
53
Mirae Asset Global Investments
Seoul,
South Korea
| – | -$60.3K | -14,244 | Closed |
|
|
MIM
54
MetLife Investment Management
Whippany,
New Jersey
| – | -$60K | -14,186 | Closed |
|
55
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| – | -$46.8K | -11,059 | Closed |
|
|
HSA
56
Hussman Strategic Advisors
Ellicott City,
Maryland
| – | -$22.2K | -5,250 | Closed |
|
|
MLICM
57
Metropolitan Life Insurance Company (MetLife)
New York
| – | -$6.22K | -1,470 | Closed |
|
58
Allspring Global Investments
Charlotte,
North Carolina
| – | -$5.09K | -1,204 | Closed |
|
59
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
| – | -$106 | -25 | Closed |
|
CARM Hedge Fund Activity: Q4 2023 in Review
50 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Carisma Therapeutics (CARM) for Q4 2023, worth a combined $26.6M — down 33% from $39.6M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of CARM and 3 opened new positions — a net loss of 8 holders — while 13 trimmed existing stakes and 18 added.
The largest buyer was Morgan Stanley, adding an estimated $410K. The largest seller was Trustees of The University of Pennsylvania, cutting an estimated $1.51M.
- 50 institutional investors held Carisma Therapeutics (CARM) as of Q4 2023, down from 58 in Q3 2023.
- Funds reported $26.6M of Carisma Therapeutics stock for Q4 2023, down 33% quarter-over-quarter.
- 3 funds opened new Carisma Therapeutics positions in Q4 2023 and 11 closed out, a net change of -8 holders.
- The largest Carisma Therapeutics buyer in Q4 2023 was Morgan Stanley, an estimated $410K added.
- The largest Carisma Therapeutics seller in Q4 2023 was Trustees of The University of Pennsylvania, an estimated $1.51M sold.
Based on aggregated 13F filings for Q4 2023.